BACKGROUND: We report the results of a multicenter randomized phase III study, assessing quality of life (QOL) in intra-arterial (IA) versus standard intravenous (IV) chemoradiation in advanced head and neck cancer. METHODS:Two hundred seven patients with inoperable stage IV disease-152 men and 55 women; mean age, 55 years-were included in this study. The patients were treated with standard radiotherapy with 4 weekly IA or 3 weekly IV cisplatin infusions. The QOL assessments carried out were EORTC-C30, H&N35, and trial-specific questionnaires. RESULTS:Overall QOL deteriorated in all patients during treatment, is gradually improving over 1 year. IA patients showed significantly less nausea and vomiting at week 7 (p <.001). IV patients were significantly more fatigued (p <.006). At 1 year, no significant difference in tube feeding was found. Voice quality slightly exceeded the pretreatment values at 1 year. Forty-two of 62 employed patients returned to work. CONCLUSION: During treatment, significantly fewer problems with nausea and vomiting occurred in IA than in IV patients. Both groups showed improved voicing and oral intake during follow-up, often exceeding pretreatment values at 1 year. (c) 2008 Wiley Periodicals, Inc. Head Neck, 2009.
RCT Entities:
BACKGROUND: We report the results of a multicenter randomized phase III study, assessing quality of life (QOL) in intra-arterial (IA) versus standard intravenous (IV) chemoradiation in advanced head and neck cancer. METHODS: Two hundred seven patients with inoperable stage IV disease-152 men and 55 women; mean age, 55 years-were included in this study. The patients were treated with standard radiotherapy with 4 weekly IA or 3 weekly IV cisplatin infusions. The QOL assessments carried out were EORTC-C30, H&N35, and trial-specific questionnaires. RESULTS: Overall QOL deteriorated in all patients during treatment, is gradually improving over 1 year. IA patients showed significantly less nausea and vomiting at week 7 (p <.001). IV patients were significantly more fatigued (p <.006). At 1 year, no significant difference in tube feeding was found. Voice quality slightly exceeded the pretreatment values at 1 year. Forty-two of 62 employed patients returned to work. CONCLUSION: During treatment, significantly fewer problems with nausea and vomiting occurred in IA than in IV patients. Both groups showed improved voicing and oral intake during follow-up, often exceeding pretreatment values at 1 year. (c) 2008 Wiley Periodicals, Inc. Head Neck, 2009.
Authors: Valesca P Retèl; Cindy van den Boer; Lotte M G Steuten; Sławomir Okła; Frans J Hilgers; Michiel W van den Brekel Journal: Eur Arch Otorhinolaryngol Date: 2015-04-02 Impact factor: 2.503
Authors: Valesca P Retèl; Lisette van der Molen; Lotte M G Steuten; Michiel W van den Brekel; Frans J M Hilgers Journal: Eur Arch Otorhinolaryngol Date: 2015-02-11 Impact factor: 2.503
Authors: Lisette van der Molen; Maya A van Rossum; Coen R N Rasch; Ludi E Smeele; Frans J M Hilgers Journal: Eur Arch Otorhinolaryngol Date: 2013-07-28 Impact factor: 2.503
Authors: Lisette van der Molen; Maya A van Rossum; Annemieke H Ackerstaff; Ludi E Smeele; Coen R N Rasch; Frans J M Hilgers Journal: BMC Ear Nose Throat Disord Date: 2009-11-15